The "Intramuscular Advantage": How 2026 is Using Modern Autoinjectors to End Injection-Site Pain.
By mid-2026, the industry has officially entered the era of "Painless Delivery." This year, the focus is on the mass adoption of Advanced Intramuscular (IM) Autoinjectors, which have reduced reports of injection-site reactions by over 35%. This innovation is a primary driver for the market, as these "Smart Pens" allow MS patients to self-administer their weekly dose with the precision of a...
0 Comentários 0 Compartilhamentos 5 Visualizações 0 Anterior